Analyst Price Target is $22.56
▲ +78.87% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $22.56, with a high forecast of $30.00 and a low forecast of $9.00. The average price target represents a 78.87% upside from the last price of $12.61.
Current Consensus is
The current consensus among 10 polled investment analysts is to moderate buy stock in Deciphera Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.